

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)	
										2022E	2023E	2024E			
1	2seventy bio, Inc.	TSVT	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	5.93	(6.82)	(4.70)	(0.13)	NA	NA	NA	50.6	300
2	4D Molecular Therapeutics, Inc.	FDMT	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	27.42	(3.32)	(2.19)	(2.72)	NA	NA	NA	42.8	1,172
3	908 Devices Inc.	MASS	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	7.23	(1.07)	(1.14)	(1.10)	NA	NA	NA	32.4	234
4	89bio, Inc.	ETNB	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	8.34	(2.93)	(2.01)	(2.28)	NA	NA	NA	90.8	757
5	Abbisko Therapeutics Co., Ltd.*	2256 HK	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	HKD 2.23	¥-0.80	¥-0.82	¥-0.95	NA	NA	NA	702.2	HKD 1,565.90
6	AbbVie Inc. @*	ABBV	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	173.84	13.77	11.10	11.17	12.6	15.7	15.6	1,765.5	306,921
7	AbCellera Biologics Inc.	ABCL	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	5.13	0.50	(0.46)	(0.45)	10.3	NA	NA	290.2	1,489
8	Abivax SA	ABVX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	12.60	(3.18)	(2.19)	(2.08)	NA	NA	NA	62.9	793
9	AC Immune SA#--	ACIU	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	2.80	(CHF 0.85)	(CHF 0.61)	(CHF 0.65)	NA	NA	NA	98.7	276
10	Acadia Healthcare Company, Inc.*#	ACHC	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	80.51	3.16	3.46	3.86	25.5	23.3	20.9	92.2	7,424
11	ACADIA Pharmaceuticals Inc.#--	ACAD	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	25.81	(1.34)	(0.33)	1.65	NA	NA	15.6	164.2	4,237
12	Aclaris Therapeutics, Inc.	ACRS	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.20	(1.33)	(1.63)	(0.94)	NA	NA	NA	70.8	85
13	Acorda Therapeutics, Inc.*	ACOR	Suspended Coverage		Biopharma / Infectious Disease. Endocrine & Healthcare Providers and Managed Care	Dec	15.15	NA	NA	NA	NA	NA	NA	46.3	701
14	AdaptHealth Corp.^	AHCO	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	7.28	0.38	(3.09)	0.54	19.2	NA	13.5	136.4	993
15	Adaptimmune Therapeutics plc#	ADAP	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	1.29	(0.17)	(0.09)	(0.07)	NA	NA	NA	227.1	293
16	Affimed N.V.#	AFMD	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	0.53	(€ 0.66)	(€ 0.73)	(€ 0.59)	NA	NA	NA	149.3	79
17	Agilent Technologies, Inc.**	A	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Oct	134.27	5.22	5.45	5.49	25.7	24.6	24.5	293.0	39,342
18	agilon health, inc.	AGL	Market Perform	Whit Mayo	Healthcare Providers and Managed Care	Dec	7.27	(0.26)	(0.35)	0.01	NA	NA	NA	410.3	2,983
19	Agios Pharmaceuticals, Inc.	AGIO	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	24.94	(4.23)	(6.30)	(6.27)	NA	NA	NA	55.9	1,394
20	AirSculpt Technologies, Inc.*#	AIRS	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	6.81	(0.25)	0.01	0.24	NA	NA	28.4	57.4	390
21	Aldeyra Therapeutics, Inc.	ALDX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	3.31	(1.06)	(0.55)	1.10	NA	NA	3.0	58.8	194
22	Alignment Healthcare, Inc.	ALHC	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	6.75	(0.82)	(0.78)	(0.53)	NA	NA	NA	189.1	1,276
23	Aligos Therapeutics, Inc.	ALGS	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	0.68	(2.25)	(1.49)	(0.60)	NA	NA	NA	75.1	51
24	Alkermes plc<	ALKS	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	26.73	0.34	1.80	3.00	78.6	14.9	8.9	166.9	4,461
25	Allakos Inc.	ALLK	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.29	(5.05)	(1.96)	(1.20)	NA	NA	NA	87.5	113
26	AlloVir, Inc.	ALVR	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	0.71	(2.20)	(1.62)	(0.29)	NA	NA	NA	114.1	81
27	Alnylam Pharmaceuticals, Inc. @*	ALNY	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	169.35	(9.30)	(2.43)	(3.04)	NA	NA	NA	131.3	22,236
28	Alpine Immune Sciences, Inc.	ALPN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	28.30	(1.73)	(1.19)	(1.61)	NA	NA	NA	58.0	1,641
29	Amarin Corporation plc<	AMRN	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Healthcare Providers and Managed Care	Dec	1.23	(0.12)	0.02	(0.10)	NA	61.3	NA	408.3	500
30	Amedisys, Inc.^	AMED	Market Perform	Whit Mayo	Healthcare Providers and Managed Care	Dec	93.90	5.00	4.11	3.97	18.8	22.8	23.7	32.6	3,065
31	Amgen Inc. @*	AMGN	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	291.37	17.68	18.65	19.54	16.5	15.6	14.9	535.2	155,935
32	Amicus Therapeutics, Inc.	FOLD	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	13.50	(0.82)	(0.46)	(0.05)	NA	NA	NA	293.2	3,959
33	Amylyx Pharmaceuticals, Inc.	AMLX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	15.76	(3.39)	0.85	1.45	NA	18.5	10.9	67.5	1,064

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)
										2022E	2023E	2024E		
34 AN2 Therapeutics, Inc.	ANTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	19.92	(2.79)	(2.94)	(3.29)	NA	NA	NA	29.7	592
35 Aptinyx Inc.	APTX	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	0.10	(1.00) E	(0.40)	(0.10)	NA	NA	NA	NA	NA
36 Arbutus Biopharma Corporation	ABUS	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Biopharma / Immuno-	Dec	2.68	NA	NA	NA	NA	NA	NA	167.7	449
37 Arcellx, Inc.	ACLX	Outperform	Daina M. Graybosch, Ph.D.	Oncology Biopharma / Immuno-	Dec	62.79	(4.56)	(2.21)	(1.01)	NA	NA	NA	48.7	3,057
38 Arcus Biosciences, Inc.	RCUS	Outperform	Daina M. Graybosch, Ph.D.	Oncology Biopharma / Immuno-	Dec	15.68	(3.71)	(4.31)	(4.24)	NA	NA	NA	74.9	1,174
39 argenx SE#	ARGX	Outperform	Thomas J. Smith	Oncology Biopharma / Immunology & Metabolism	Dec	401.96	(13.05)	(4.28)	(4.99)	NA	NA	NA	59.2	23,794
40 Arrowhead Pharmaceuticals, Inc.	ARWR	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Sep	31.43	(1.67)	(1.92) A	(1.26)	NA	NA	NA	123.9	3,893
41 ARS Pharmaceuticals, Inc.	SPRY	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Biopharma / Targeted	Dec	6.57	(0.87)	(0.60)	(0.60)	NA	NA	NA	96.0	631
42 Arvinas, Inc.@*	ARVN	Outperform	Christopher Liu, Pharm.D.	Oncology Biopharma / Rare Diseases	Dec	51.75	(5.31)	(3.89)	(6.43)	NA	NA	NA	94.9	4,911
43 Ascendis Pharma A/S	ASND	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	140.63	(€ 10.40)	(€ 8.55)	(€ 5.22)	NA	NA	NA	57.7	8,115
44 Assembly Biosciences, Inc.	ASMB	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Biopharma / Targeted	Dec	1.02	(2.20)	NA	NA	NA	NA	NA	65.8	67
45 AstraZeneca PLC^#	AZN	Outperform	Andrew Berens, M.D.	Oncology Biopharma / Infectious Disease, Endocrine & Biopharma / Targeted	Dec	62.37	3.33	3.70	4.00	18.7	16.9	15.6	1,560.0	97,297
46 Atea Pharmaceuticals, Inc.	AVIR	Market Perform	Roanna Ruiz, Ph.D.	Oncology Biopharma / Rare Diseases	Dec	4.27	(1.39)	(1.65)	(2.80)	NA	NA	NA	83.4	356
47 Aura Biosciences, Inc.~#	AURA	Outperform	Andrew Berens, M.D.	Oncology Biopharma / Rare Diseases	Dec	8.47	(1.96)	(1.80)	(1.83)	NA	NA	NA	49.2	417
48 Aurinia Pharmaceuticals Inc.	AUPH	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	8.12	(0.76)	(0.50)	(0.28)	NA	NA	NA	143.6	1,166
49 Avadel Pharmaceuticals plc	AVDL	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	14.91	(2.29)	(1.95)	(0.20)	NA	NA	NA	89.8	1,339
50 Avidity Biosciences, Inc.	RNA	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	13.01	(3.34)	(3.00)	(3.87)	NA	NA	NA	74.1	964
51 Axogen, Inc.~^~	AXGN	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	9.86	(0.30)	(0.12)	0.07	NA	NA	NA	43.0	424
52 Axonics, Inc.	AXNX	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	67.82	(1.28)	(0.19)	0.26	NA	NA	NA	50.7	3,436
53 Axsome Therapeutics, Inc.#~~	AXSM	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	97.34	(4.57)	(4.28)	(4.00)	NA	NA	NA	47.3	4,606
54 Beam Therapeutics, Inc.	BEAM	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	28.85	(4.13)	(2.10)	(3.98)	NA	NA	NA	81.5	2,351
55 BeiGene, Ltd.~+	BGNE	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	143.80	(19.43)	(7.91)	(12.28)	NA	NA	NA	104.7	15,056
56 Belite Bio, Inc#~~	BLTE	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	45.76	(0.63)	(1.40)	0.10	NA	NA	NA	25.2	1,154
57 Bicycle Therapeutics plc	BCYC	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	17.00	(3.80)	(4.94)	(4.47)	NA	NA	NA	37.7	641
58 Biogen Inc.@*	BIIB	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	239.59	17.69	14.80	16.35	13.5	16.2	14.7	144.9	34,716
59 Biohaven Ltd.~^~	BHVN	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	48.15	(12.75)	(5.45)	(5.85)	NA	NA	NA	80.2	3,863
60 BioMarin Pharmaceutical Inc.	BMRN	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	88.25	0.75	1.03	1.21	NA	85.7	72.9	188.4	16,623
61 BioNTech SE#	BNTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	92.43	37.77	4.60	(0.71)	2.4	20.1	NA	243.0	22,461
62 Bio-Rad Laboratories, Inc.**	BIO	Suspended Coverage		Life Science Tools and Diagnostics	Dec	325.36	NA	NA	NA	NA	NA	NA	29.1	9,483
63 Bio-Techne Corporation**	TECH	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Jun	67.20	1.97	1.99) A	1.78	34.1	33.8	37.8	157.2	10,563
64 bluebird bio, Inc.@*	BLUE	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	1.05	(3.84)	(1.53)	(1.07)	NA	NA	NA	192.7	201
65 Blueprint Medicines Corporation	BPMC	Underperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	76.80	(9.35)	(8.42)	(6.14)	NA	NA	NA	60.8	4,668
66 Bolt Biotherapeutics, Inc.	BOLT	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.07	(2.39)	(1.65)	(1.70)	NA	NA	NA	38.0	41
67 Brii Biosciences Limited#	2137 HK	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	HKD 1.75	¥-0.67	¥-1.30	¥-1.35	NA	NA	NA	729.6 HKD	1,276.83
68 BridgeBio Pharma, Inc.	BBIO	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	34.05	(3.25)	(3.80)	(3.26)	NA	NA	NA	174.0	5,924

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E		Shares Outstanding	Market Cap
													(MM)	(\$MM)		
69	Bristol-Myers Squibb Company	BMY	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	49.15	7.70	7.51	A	6.91	6.4	6.5	7.1	2,034.8	100,008
70	Bruker Corporation**	BRKR	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	70.82	2.33	2.56		2.86	30.4	27.7	24.8	138.4	9,802
71	C4 Therapeutics, Inc.@*	CCCC	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	6.07	(2.62)	(2.56)		(2.95)	NA	NA	NA	49.3	299
72	CareDx, Inc.	CDNA	Suspended Coverage		Life Science Tools and Diagnostics	Dec	8.83	NA	NA		NA	NA	NA	NA	54.1	478
73	Caribou Biosciences, Inc.	CRBU	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	6.82	(1.66)	(1.21)		(1.62)	NA	NA	NA	88.4	603
74	Castle Biosciences, Inc.	CSTL	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	23.82	(3.28)	(3.00)		(2.70)	NA	NA	NA	26.9	641
75	Celldex Therapeutics, Inc.	CLDX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	37.36	(2.40)	(2.77)		(2.94)	NA	NA	NA	54.7	2,043
76	Centessa Pharmaceuticals plc	CNTA	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	8.62	(2.31)	(1.57)		(1.49)	NA	NA	NA	97.6	841
77	Century Therapeutics, Inc.	IPSC	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	4.32	(2.27)	(2.17)		(1.95)	NA	NA	NA	59.8	258
78	Cidara Therapeutics, Inc.	CDTX	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Healthcare Providers and	Dec	0.69	NA	NA		NA	NA	NA	NA	90.4	62
79	The Cigna Group~*^	CI	Market Perform	Whit Mayo	Managed Care Healthcare Providers and	Dec	333.15	23.26	25.09	A	28.34	14.3	13.3	11.8	292.5	97,446
80	Clover Health Investments, Corp.	CLOV	Market Perform	Whit Mayo	Managed Care Healthcare Providers and	Dec	1.03	(0.71)	(0.48)		(0.10)	NA	NA	NA	480.8	493
81	Cogent Biosciences, Inc.	COGT	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	6.32	(2.39)	(2.45)		(2.59)	NA	NA	NA	86.1	544
82	Compass Therapeutics, Inc.	CMPX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	1.47	(0.37)	(0.31)		(0.47)	NA	NA	NA	127.5	187
83	Compugen Ltd.	CGEN	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	2.16	(0.39)	(0.16)		(0.62)	NA	NA	NA	88.3	190
84	Connect Biopharma Holdings Limited#	CNTB	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.21	(CNY 14.48)	(CNY 5.92)		(CNY 3.90)	NA	NA	NA	55.1	67
85	Crinetix Pharmaceuticals, Inc.	CRNX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	38.97	(3.15)	(3.75)		(4.15)	NA	NA	NA	66.8	2,603
86	CRISPR Therapeutics AG	CRSP	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	71.28	(8.36)	(2.73)		(7.60)	NA	NA	NA	79.4	5,662
87	Cryoport, Inc.	CYRX	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	15.90	(0.93)	(1.09)		(1.13)	NA	NA	NA	49.0	779
88	Cullinan Oncology, Inc.	CGEM	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	18.10	2.38	(4.14)		(4.06)	7.6	NA	NA	42.8	774
89	CureVac N.V.	CVAC	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	3.44	(1.32)	(0.89)		(0.54)	NA	NA	NA	223.9	769
90	CymaBay Therapeutics, Inc.*##	CBAY	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	25.92	(1.21)	(0.96)		(1.56)	NA	NA	NA	102.2	2,648
91	Cytokinetics, Incorporated	CYTK	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	78.82	(4.25)	(4.58)		(4.22)	NA	NA	NA	98.1	7,728
92	Danaher Corporation^	DHR	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	245.12	10.95	8.53	A	7.65	22.4	28.7	32.0	739.2	181,193
93	Deciphera Pharmaceuticals, Inc.	DCPH	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	15.27	(2.37)	(2.29)	A	(1.96)	NA	NA	NA	80.8	1,233
94	Denali Therapeutics Inc.	DNLI	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	17.23	(2.60)	(1.10)		(3.55)	NA	NA	NA	138.2	2,381
95	Design Therapeutics, Inc.	DSGN	Market Perform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	2.30	(1.14)	(1.27)		(1.05)	NA	NA	NA	56.0	129
96	DexCom, Inc.@*	DXCM	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	122.77	0.82	1.28		1.85	NA	95.9	66.4	415.9	51,060
97	Disc Medicine, Inc.	IRON	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	67.40	(45.05)	(3.11)		(4.00)	NA	NA	NA	24.1	1,627
98	Edgewise Therapeutics, Inc.	EWTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	20.43	(1.26)	(1.60)		(2.72)	NA	NA	NA	85.3	1,742
99	Editas Medicine, Inc.	EDIT	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	7.38	(3.21)	(1.54)		(1.51)	NA	NA	NA	81.7	602
100	Edwards Lifesciences Corporation~^~	EW	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	85.57	2.48	2.51	A	2.75	34.5	34.1	31.1	606.5	51,898
101	Eledon Pharmaceuticals, Inc.	ELDN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.71	(6.16)	(1.73)		(0.93)	NA	NA	NA	30.0	51
102	Elevance Health, Inc.^	ELV	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	503.40	29.05	33.11	A	37.17	17.3	15.2	13.5	235.0	118,277
103	Elevation Oncology, Inc.@*	ELEV	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	2.90	(4.09)	(1.45)		(1.17)	NA	NA	NA	42.4	123

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)	
										2022E	2023E	2024E			
104	Eli Lilly and Company@*	LLY	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	741.32	7.94	6.32	12.44	93.4	NA	59.6	949.3	703,740
105	Enanta Pharmaceuticals, Inc.	ENTA	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Healthcare Providers and	Sep	12.40	(5.91)	(6.38)	(5.40)	NA	NA	NA	21.2	262
106	Enhabit, Inc.	EHAB	Underperform	Whit Mayo	Managed Care	Dec	9.04	1.38	0.19	0.06	6.5	47.6	NA	50.1	453
107	Equillium, Inc.*##	EQ	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.67	(1.85)	(0.42)	0.32	NA	NA	5.2	35.1	59
108	Evolut Health, Inc.~~~	EVH	Suspended Coverage		Tech-Enabled Healthcare Services	Dec	30.62	NA	NA	NA	NA	NA	NA	115.0	3,520
109	Evolus, Inc.#~~	EOLS	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	13.54	(1.33)	(1.12)	(0.90)	NA	NA	NA	57.2	774
110	EXACT Sciences Corporation^	EXAS	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	61.29	(3.54)	(1.36)	(0.71)	NA	NA	NA	180.8	11,084
111	Exelixis, Inc.~^~	EXEL	Market Perform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	20.20	0.82	0.90 A	1.60	24.6	22.4	12.6	303.2	6,123
112	Fate Therapeutics, Inc.	FATE	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	6.11	(2.91)	(1.99)	(2.60)	NA	NA	NA	98.6	602
113	FibroGen, Inc.	FGEN	Suspended Coverage		Biopharma / Immunology & Metabolism	Dec	2.63	(2.01)	NA	NA	NA	NA	NA	98.3	259
114	Fulcrum Therapeutics, Inc.#~~	FULC	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	8.64	(2.44)	(1.63)	(1.71)	NA	NA	NA	61.8	534
115	Fusion Pharmaceuticals Inc.@*	FUSN	Outperform	Faisal A. Khurshid	Biopharma / Emerging Oncology	Dec	11.02	(2.00)	(1.35)	(1.39)	NA	NA	NA	72.4	798
116	Galapagos NV*##	GLPG	Suspended Coverage		Biopharma / Immunology & Metabolism	Dec	39.44	NA	NA	NA	NA	NA	NA	65.9	2,599
117	Galecto, Inc.	GLTO	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	0.63	(2.43)	(1.56)	(1.13)	NA	NA	NA	27.1	17
118	Genmab A/S#	GMAB	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	27.71	DKK 83.65	DKK 75.74	DKK 77.81	0.3	0.4	0.4	660.7	18,308
119	GENFIT S.A.#	GNFT	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	3.66	(€ 0.48)	€ 0.42	€ 0.33	NA	8.7	11.1	49.8	182
120	Gilead Sciences, Inc.~^~	GILD	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	73.71	7.26	6.72 A	7.04	10.2	11.0	10.5	1,246.0	91,846
121	GlaxoSmithKline plc~~#	GSK	Suspended Coverage		Biopharma / Diversified Biotechnology	Dec	£16.57	NA	NA	NA	NA	NA	NA	5,063.0	83,914
122	Gossamer Bio, Inc.@*	GOSS	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	0.86	(2.71)	(1.23)	(0.99)	NA	NA	NA	225.4	193
123	Guardant Health, Inc.**^	GH	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	22.47	(4.28)	(3.32)	(3.00)	NA	NA	NA	121.4	2,727
124	Halozyyme Therapeutics, Inc.@*	HALO	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	35.06	2.21	2.79	3.86	15.9	12.6	9.1	132.1	4,631
125	Harpoon Therapeutics, Inc.	HARP	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	22.34	(2.04)	(3.26)	(2.27)	NA	NA	NA	16.9	379
126	HCA Healthcare, Inc.*#	HCA	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	306.76	16.88	18.98 A	20.22	18.2	16.2	15.2	267.7	82,106
127	HilleVax, Inc.@*	HLVX	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	15.08	(5.89)	(3.13)	(3.40)	NA	NA	NA	48.4	730
128	Hologic, Inc.^	HOLX	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Sep	73.80	6.01	3.96 A	4.04	12.3	18.6	18.3	234.7	17,323
129	HOOKIPA Pharma Inc.@*	HOOK	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	0.67	(0.99)	(0.66)	(0.24)	NA	NA	NA	81.6	55
130	Humana Inc.~#^	HUM	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	368.08	25.22	25.99 A	16.02	14.6	14.2	23.0	123.1	45,315
131	IDEAYA Biosciences, Inc.	IDYA	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	46.00	(1.42)	(1.91)	(2.79)	NA	NA	NA	60.0	2,760
132	illumina, Inc.**	ILMN	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	139.49	2.11	0.87	0.91	66.1	NA	NA	158.8	22,150
133	Immatics N.V.#	IMTX	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	11.34	€ 0.56	(€ 1.19)	(€ 0.56)	20.3	NA	NA	100.6	1,141
134	Immunic, Inc.	IMUX	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.26	(3.78)	(2.19)	(1.16)	NA	NA	NA	89.9	113

Source: Leerink Partners LLC, FactSet, and company data

Leerink Partners Coverage List

															Updated on:	
															2/9/2024	
Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E		Shares Outstanding (MM)	Market Cap (\$MM)
135	ImmunoGen, Inc.	IMGN	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	31.25	(0.88)	0.02	0.20	NA	NA	NA	279.4	8,728	
136	Immunome, Inc.@*	IMNM	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	23.86	(3.09)	(0.50)	(2.68)	NA	NA	NA	42.7	1,020	
137	Immunovant, Inc.@*	IMVT	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Mar	35.75	(1.43)	(1.71)	(1.79)	NA	NA	NA	130.4	4,662	
138	Incyte Corporation	INCY	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	57.51	1.52	2.48	3.98	37.8	23.2	14.4	224.1	12,889	
139	inflaRx N.V.#	IFRX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	1.60	(0.67)	(0.70)	(0.60)	NA	NA	NA	58.9	94	
140	Innate Pharma S.A.#	IPHA	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	€ 2.23	(€ 0.73)	(€ 0.48)	(€ 1.09)	NA	NA	NA	80.9	180	
141	Innoviva, Inc.	INVA	Suspended Coverage		Biotechnology	Dec	15.47	NA	NA	NA	NA	NA	NA	64.1	991	
142	Insmed Incorporated	INSM	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	28.65	(3.91)	(5.09)	(4.06)	NA	NA	NA	143.1	4,099	
143	Inspire Medical Systems, Inc.	INSP	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	200.88	(1.60)	(0.72) A	(0.08)	NA	NA	NA	29.5	5,931	
144	Insulet Corporation**^	PODD	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	195.13	0.07	2.13	3.41	NA	91.6	57.2	69.8	13,625	
145	Intellia Therapeutics, Inc.@*	NTLA	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	28.28	(6.16)	(4.96)	(4.65)	NA	NA	NA	89.6	2,533	
146	Intra-Cellular Therapies, Inc.#~	ITCI	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	71.85	(2.72)	(1.60)	(0.60)	NA	NA	NA	96.2	6,915	
147	Intuitive Surgical, Inc.^	ISRG	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	386.08	4.68	5.71 A	6.33	82.5	67.6	61.0	352.3	136,026	
148	Ionis Pharmaceuticals, Inc.@*	IONS	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	50.98	(1.66)	(2.35)	(3.72)	NA	NA	NA	143.5	7,314	
149	Ironwood Pharmaceuticals, Inc.	IRWD	Suspended Coverage		Specialty Pharmaceuticals	Dec	15.10	NA	NA	NA	NA	NA	NA	156.1	2,357	
150	iTeos Therapeutics, Inc.	ITOS	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	10.85	2.56	(2.44)	(8.78)	4.2	NA	NA	35.8	388	
151	Jazz Pharmaceuticals plc*#	JAZZ	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	123.03	13.13	18.50	20.50	9.4	6.7	6.0	63.0	7,745	
152	Johnson & Johnson@*	JNJ	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	156.56	8.93	9.92 A	10.64	17.5	15.8	14.7	2,407.3	376,884	
153	KalVista Pharmaceuticals, Inc.	KALV	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Apr	15.84	(3.36)	(3.32)	(2.85)	NA	NA	NA	34.6	547	
154	Karuna Therapeutics, Inc.	KRTX	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	316.69	(8.74)	(5.45)	(9.30)	NA	NA	NA	37.9	12,000	
155	Karyopharm Therapeutics Inc.	KPTI	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	1.52	(2.02)	(1.15)	(0.96)	NA	NA	NA	114.5	174	
156	Keros Therapeutics, Inc.@*	KROS	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	52.70	(4.15)	(5.28)	(5.38)	NA	NA	NA	33.5	1,763	
157	Kinnate Biopharma Inc.	KNTE	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	2.29	(2.64)	(2.35)	(1.30)	NA	NA	NA	47.1	108	
158	Kura Oncology, Inc.	KURA	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	20.78	(2.03)	(2.13)	(2.30)	NA	NA	NA	74.3	1,544	
159	Kymera Therapeutics, Inc.	KYMR	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	34.93	(2.87)	(2.20)	(3.24)	NA	NA	NA	59.4	2,074	
160	Landos Biopharma, Inc.	LABP	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	5.30	(9.75)	(3.41)	(2.03)	NA	NA	NA	3.1	17	
161	Lantheus Holdings, Inc.*#	LNTH	Outperform	Roanna Ruiz, Ph.D.	Medical Supplies and Devices	Dec	55.79	4.22	5.83	5.93	13.2	9.6	9.4	68.5	3,821	
162	LAVA Therapeutics N.V.	LVTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.70	(€ 1.24)	(€ 0.84)	(€ 1.35)	NA	NA	NA	26.3	45	
163	Lexeo Therapeutics, Inc.	LXEO	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	16.78	(36.36)	(2.68)	(2.84)	NA	NA	NA	26.6	447	
164	H. Lundbeck A/S^*	HLUNB DC	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	DKK 32.32	DKK 3.74	DKK 4.22	DKK 4.45	8.6	7.7	7.3	995.7	DKK 32,182.35	
165	MacroGenics, Inc.	MGNX	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	18.00	(1.95)	0.36	(1.31)	NA	50.0	NA	62.0	1,117	
166	Madrigal Pharmaceuticals, Inc.*##	MDGL	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	171.53	(17.23)	(19.62)	(18.02)	NA	NA	NA	19.7	3,386	
167	MannKind Corporation*##	MNKD	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	3.45	(0.34)	(0.07)	0.08	NA	NA	43.1	269.6	929	
168	Marinus Pharmaceuticals, Inc.#~	MRNS	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	10.15	(0.41)	(2.55)	(2.30)	NA	NA	NA	54.6	554	
169	Merck & Co., Inc.	MRK	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	125.99	7.48	1.51 A	8.51	16.8	83.4	14.8	2,534.0	319,249	

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding	Market Cap
										2022E	2023E	2024E	(MM)	(\$MM)
170 Mereo BioPharma Group plc	MREO	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	4.00	(0.06)	(0.05)	0.07	NA	NA	57.1	28.0	112
171 Mersana Therapeutics, Inc.	MRSN	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncoloav	Dec	4.22	(2.18)	(1.45)	(0.55)	NA	NA	NA	120.6	509
172 Merus N.V.@*	MRUS	Outperform	Andrew Berens, M.D.	Biopharma / Immuno-Oncoloav	Dec	40.97	(2.92)	(2.74)	(3.89)	NA	NA	NA	57.7	2,365
173 Mirum Pharmaceuticals, Inc.	MIRM	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic	Dec	27.33	(4.01)	(3.72)	1.57	NA	NA	17.4	46.6	1,274
174 Moderna, Inc.	MRNA	Underperform	Mani Foroohar, M.D.	Medicine Biopharma / Genetic	Dec	89.11	20.10	(11.30)	(7.39)	4.4	NA	NA	381.3	33,976
175 Molecular Partners AG#	MOLN	Market Perform	Daina M. Graybosch, Ph.D.	Medicine Biopharma / Immuno-Oncoloav	Dec	4.56	CHF 3.72	(CHF 1.88)	(CHF 2.44)	1.2	NA	NA	36.4	166
176 Monte Rosa Therapeutics, Inc.@*	GLUE	Market Perform	Christopher Liu, Pharm.D.	Oncoloav Biopharma / Targeted	Dec	4.76	(2.30)	(1.72)	(1.95)	NA	NA	NA	50.1	238
177 MoonLake Immunotherapeutics AG	MLTX	Outperform	Thomas J. Smith	Oncoloav Biopharma / Immunology & Metabolism	Dec	63.27	(1.70)	(0.81)	(0.92)	NA	NA	NA	59.9	3,792
178 Morphic Holding, Inc.	MORF	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	39.54	(1.55)	(3.30)	(3.47)	NA	NA	NA	49.7	1,967
179 MorphoSys AG#	MOR GY	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	€ 64.06	(€ 4.42)	(€ 10.97)	(€ 6.89)	NA	NA	NA	37.7	€ 2,412
180 Myriad Genetics, Inc.~	MYGN	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	22.51	(0.30)	(0.31)	(0.05)	NA	NA	NA	82.2	1,850
181 Nabriva Therapeutics plc#	NBRV	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Biopharma / Emerging	Dec	0.00	NA	NA	NA	NA	NA	NA	3.2	0
182 Nanobiotix S.A.#	NBTX	Outperform	Jonathan Chang, Ph.D., CFA	Oncoloav Life Science Tools and Diagnostics	Dec	7.50	(1.64)	(1.55)	(0.75)	NA	NA	NA	47.1	353
183 NanoString Technologies, Inc.^	NSTG	Suspended Coverage		Life Science Tools and Diagnostics	Dec	0.33	NA	NA	NA	NA	NA	NA	48.1	16
184 Natera, Inc.	NTRA	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	69.87	(5.57)	(3.84)	(2.85)	NA	NA	NA	120.2	8,395
185 NeoGenomics, Inc.	NEO	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	14.66	(0.56)	(0.16)	(0.08)	NA	NA	NA	127.5	1,868
186 Neurocrine Biosciences, Inc.~#	NBIX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	133.55	1.53	2.42	4.70	87.3	55.2	28.4	98.3	13,121
187 NeuroPace, Inc.	NPCE	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	16.86	(1.91)	(1.34)	(1.27)	NA	NA	NA	26.3	443
188 NewAmsterdam Pharma Company N.V.#	NAMS	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Biopharma / Immuno-Oncology	Dec	20.13	(€ 0.96)	(€ 1.93)	(€ 1.40)	NA	NA	NA	82.3	1,657
189 Nkarta, Inc.	NKTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	11.06	(2.65)	(3.07)	(3.09)	NA	NA	NA	49.1	543
190 Novartis AG	NVS	Suspended Coverage		Pharmaceuticals/ Major	Dec	100.87	NA	NA	NA	NA	NA	NA	2,277.5	229,729
191 NovoCure Limited@*	NVCR	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncoloav	Dec	15.16	(0.88)	(2.07)	(1.83)	NA	NA	NA	106.9	1,620
192 Novo Nordisk A/S	NVO	Suspended Coverage		Pharmaceuticals/ Major	Dec	DKK 830.00	NA	NA	NA	NA	NA	NA	2,456.0	DKK 2,038,480.00
193 Nurix Therapeutics, Inc.@*	NRIX	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncoloav	Nov	8.74	(3.71)	(1.53)	(4.13)	NA	NA	NA	48.5	424
194 Nuvalent, Inc.	NUVL	Market Perform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncoloav	Dec	82.65	(1.65)	(2.24)	(3.36)	NA	NA	NA	57.2	4,727
195 Oculis Holding AG	OCS	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	12.78	CHF 0.00	(CHF 4.95)	(CHF 1.30)	NA	NA	NA	36.6	468
196 Olink Holding AB@*	OLK	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	24.41	(0.08)	(0.05)	(0.08)	NA	NA	NA	124.3	3,035
197 OmniAb, Inc.	OABI	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	5.35	(0.27)	(0.57)	(0.62)	NA	NA	NA	116.2	621
198 Opthea Limited	OPT	Outperform	Marc Goodman	Biopharma / Neuroscience	Jun	2.84	(0.26)	(0.32)	(0.21)	NA	NA	NA	82.9	235
199 Pediatrix Medical Group, Inc.^	MD	Market Perform	Whit Mayo	Healthcare Providers and Managed Care	Dec	8.88	1.66	1.30	1.16	5.3	6.8	7.7	84.0	746
200 PepGen Inc.	PEPG	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	14.72	(4.42)	(3.58)	(4.36)	NA	NA	NA	23.8	351
201 PerkinElmer, Inc.**	PKI	Suspended Coverage		Life Science Tools and Diagnostics	Dec	104.14	NA	NA	NA	NA	NA	NA	123.4	12,852
202 Pfizer Inc.@*	PFE	Market Perform	David Risinger, CFA	Biopharma / Diversified Pharmaceuticals	Dec	27.42	6.58	1.84 A	2.25	4.2	14.9	12.2	5,646.4	154,825
203 Pharvaris N.V.	PHVS	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	28.97	(€ 2.27)	(€ 2.33)	(€ 2.01)	NA	NA	NA	40.9	1,184
204 Pliant Therapeutics, Inc.	PLRX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	17.18	(2.94)	(2.80)	(3.38)	NA	NA	NA	59.9	1,029

Source: Leerink Partners LLC, FactSet, and company data

Leerink Partners Coverage List

															Updated on:	
															2/9/2024	
Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	P/E			Shares Outstanding (MM)	Market Cap (\$MM)	
											2023E	2024E				
205	Privia Health Group, Inc.	PRVA	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	20.62	(0.10)	0.22	0.31	NA	93.7	66.5	118.1	2,434	
206	PROCEPT BioRobotics Corporation	PRCT	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	49.51	(1.96)	(2.09)	(1.96)	NA	NA	NA	50.5	2,500	
207	Prothena Corporation plc	PRTA	Outperform	Rudy Li, Ph.D., CFA	Biopharma / Neuroscience	Dec	28.44	(2.50)	(2.54)	(3.90)	NA	NA	NA	53.7	1,526	
208	PTC Therapeutics, Inc.	PTCT	Market Perform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	25.47	(7.79)	(5.69)	(4.52)	NA	NA	NA	75.5	1,922	
209	PureTech Health plc#	PRTC	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	23.97	(1.77)	(3.95)	(2.73)	NA	NA	NA	27.7	663	
210	Pyxis Oncology, Inc.	PYXS	Outperform	Jeffrey La Rosa	Biopharma / Immunology	Dec	4.40	(3.70)	(2.05)	(1.19)	NA	NA	NA	44.3	195	
211	QIAGEN N.V.**	QGEN	Suspended Coverage		Life Science Tools and Diagnostics	Dec	43.88	NA	NA	NA	NA	NA	NA	221.2	9,705	
212	Quanterix Corporation*#	QTRX	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	24.40	(1.78)	(0.74)	(0.70)	NA	NA	NA	37.8	923	
213	RAPT Therapeutics, Inc.	RAPT	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	26.00	(2.58)	(3.03)	(3.41)	NA	NA	NA	34.4	894	
214	Recursion Pharmaceuticals, Inc.	RRX	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic	Dec	10.16	(1.36)	(1.76)	(1.77)	NA	NA	NA	208.3	2,115	
215	Regeneron Pharmaceuticals, Inc. @*	REGN	Outperform	David Risinger, CFA	Biopharmaceuticals	Dec	953.04	44.98	43.79	47.34	21.2	21.8	20.1	107.9	102,875	
216	REGENXBIO Inc. @*	RGNX	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic	Dec	17.43	(6.50)	(5.76)	(4.07)	NA	NA	NA	44.0	767	
217	Relay Therapeutics, Inc.	RLAY	Outperform	Christopher Liu, Pharm.D.	Medicine	Dec	8.89	(2.59)	(2.89)	(2.59)	NA	NA	NA	127.5	1,133	
218	Relmada Therapeutics, Inc. #~	RLMD	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	5.27	(5.30)	(3.35)	(3.15)	NA	NA	NA	30.1	159	
219	Reneo Pharmaceuticals, Inc.	RPHM	Market Perform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	1.70	(2.12)	(2.42)	(0.63)	NA	NA	NA	33.3	57	
220	Repligen Corporation*#	RGEN	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	207.49	3.28	1.75	1.76	63.3	NA	NA	55.8	11,585	
221	Replimune Group, Inc.	REPL	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging	Mar	7.91	(2.99)	(3.26)	(2.98)	NA	NA	NA	59.1	467	
222	Revolution Medicines, Inc.	RVMD	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging	Dec	31.06	(3.08)	(3.37)	(2.76)	NA	NA	NA	163.8	5,087	
223	Rigel Pharmaceuticals, Inc.	RIGL	Suspended Coverage		Biopharma / Immunology & Metabolism	Dec	1.18	NA	NA	NA	NA	NA	NA	174.4	205	
224	Rocket Pharmaceuticals, Inc. @*	RCKT	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic	Dec	29.73	(3.26)	(3.04)	(1.93)	NA	NA	NA	90.2	2,680	
225	Roivant Sciences Ltd. @*	ROIV	Outperform	David Risinger, CFA	Medicine	Mar	10.90	(0.85)	(1.15)	(0.90)	NA	NA	NA	803.9	8,759	
226	Sage Therapeutics, Inc. #~	SAGE	Market Perform	Marc Goodman	Biopharmaceuticals	Dec	23.92	(8.98)	(10.25)	(5.90)	NA	NA	NA	60.0	1,436	
227	Sanofi*#	SAN FP	Outperform	David Risinger, CFA	Biopharma / Diversified	Dec	€ 86.02	€ 8.26	€ 8.11	€ 7.51	10.4	10.6	11.5	1,264.8	€ 108,797.88	
228	Sarepta Therapeutics, Inc.	SRPT	Outperform	Joseph P. Schwartz	Biopharmaceuticals	Dec	129.03	(8.03)	(6.41)	6.50	NA	NA	19.9	93.5	12,070	
229	scPharmaceuticals Inc.	SCPH	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious	Dec	5.11	(1.30)	(1.59)	(1.55)	NA	NA	NA	35.9	183	
230	Selecta Biosciences, Inc. @*	SELB	Suspended Coverage		Disease, Endocrine & Biopharma / Rare	Dec	0.69	0.10	NA	NA	6.9	NA	NA	161.9	112	
231	Shockwave Medical, Inc.	SWAV	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	235.96	5.70	3.87	6.04	41.4	61.0	39.1	36.9	8,706	
232	Sio Gene Therapies, Inc.	SIOX	Suspended Coverage		Biopharma / Genetic	Mar	0.48	NA	NA	NA	NA	NA	NA	73.5	35	
233	Solid Biosciences Inc.	SLDB	Market Perform	Joseph P. Schwartz	Medicine	Dec	7.26	(10.10)	(4.79)	(3.99)	NA	NA	NA	37.4	272	
234	Spruce Biosciences, Inc.	SPRB	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	4.10	(1.96)	(1.43)	(1.69)	NA	NA	NA	40.7	167	
235	Stoke Therapeutics, Inc.	STOK	Outperform	Rudy Li, Ph.D., CFA	Biopharma / Neuroscience	Dec	4.51	(2.60)	(2.26)	(2.00)	NA	NA	NA	44.7	201	
236	Structure Therapeutics Inc.	GPCR	Outperform	David Risinger, CFA	Biopharma / Diversified	Dec	47.58	(5.51)	(0.87)	(0.83)	NA	NA	NA	45.6	2,169	
237	Surgery Partners, Inc.*#	SGRY	Outperform	Whit Mayo	Biopharmaceuticals	Dec	33.10	0.16	0.95	1.06	NA	34.8	31.2	134.5	4,452	
238	Synlogic, Inc.	SYBX	Market Perform	Joseph P. Schwartz	Healthcare Providers and Managed Care	Dec	1.64	(0.92)	(1.35)	(1.74)	NA	NA	NA	9.2	15	
239	Tandem Diabetes Care, Inc.	TNDM	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	23.06	(1.47)	(3.18)	(1.27)	NA	NA	NA	65.2	1,503	
240	Tango Therapeutics, Inc. @*	TNGX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted	Dec	12.35	(1.23)	(1.03)	(1.16)	NA	NA	NA	102.0	1,260	
241	Tenaya Therapeutics, Inc.	TNYA	Outperform	Mani Foroohar, M.D.	Oncology	Dec	5.48	(2.76)	(1.78)	(1.99)	NA	NA	NA	94.4	517	
242	Tenet Healthcare Corporation*#	THC	Outperform	Whit Mayo	Biopharma / Genetic	Dec	88.67	6.83	6.98	6.31	13.0	12.7	14.1	101.6	9,005	

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)	
										2022E	2023E	2024E			
243	Theravance Biopharma, Inc.	TBPH	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	8.43	(1.26)	(0.89)	(0.28)	NA	NA	NA	49.8	420
244	Thermo Fisher Scientific Inc.**	TMO	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	551.32	23.24	21.54	21.51	23.7	25.6	25.6	386.4	213,015
245	Tourmaline Bio, Inc.-#	TRML	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	36.73	(17.91)	(3.36)	(2.33)	NA	NA	NA	25.6	942
246	Traverse Therapeutics, Inc.	TVTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	8.42	(4.37)	(1.72)	(2.86)	NA	NA	NA	75.1	633
247	Trevi Therapeutics, Inc.	TRVI	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.53	(0.45)	(0.30)	(0.45)	NA	NA	NA	99.5	152
248	Turnstone Biologics Corp.	TSBX	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	2.24	(1.56)	(2.27)	(2.82)	NA	NA	NA	23.1	52
249	Twist Bioscience Corporation^	TWST	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Sep	37.39	(4.03)	(3.60)	(3.08)	NA	NA	NA	57.5	2,150
250	Ultragenyx Pharmaceutical Inc.	RARE	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	46.01	(10.12)	(8.43)	(5.60)	NA	NA	NA	82.1	3,778
251	uniQure N.V.	QURE	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	5.68	(2.71)	(6.40)	(3.85)	NA	NA	NA	47.8	272
252	UnitedHealth Group Incorporated^	UNH	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	518.34	22.20	25.11	27.71	23.3	20.6	18.7	935.0	484,643
253	United Therapeutics Corporation	UTHR	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease. Endocrine & Healthcare Providers and Managed Care	Dec	210.41	16.01	20.97	22.50	13.1	10.0	9.4	47.0	9,888
254	Universal Health Services, Inc.*#	UHS	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	162.31	9.88	10.47	12.43	16.4	15.5	13.1	70.8	11,498
255	Vaxcyte, Inc.@*	PCVX	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	74.91	(3.44)	(3.32)	(4.26)	NA	NA	NA	106.1	7,947
256	Veracyte, Inc.	VCYT	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	25.31	0.00	0.13	0.13	NA	NA	NA	73.0	1,849
257	Verastem, Inc.	VSTM	Suspended Coverage		Biopharma / Immuno-Oncology	Dec	13.45	NA	NA	NA	NA	NA	NA	25.3	340
258	Vericel Corporation@*	VCEL	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	46.62	(0.35)	(0.13)	0.19	NA	NA	NA	47.7	2,225
259	Vertex Pharmaceuticals Incorporated+	VRTX	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	422.79	14.76	15.23	17.07	28.6	27.8	24.8	257.7	108,945
260	Vincorx Pharma, Inc.	VINC	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	1.43	(3.11)	(2.08)	(0.50)	NA	NA	NA	21.4	31
261	Viking Therapeutics, Inc.*##	VKTX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	29.44	(0.90)	(0.91)	(1.07)	NA	NA	NA	100.5	2,958
262	Vir Biotechnology, Inc.	VIR	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease. Endocrine & Biopharma / Targeted	Dec	9.37	3.89	(4.86)	(5.30)	2.4	NA	NA	134.5	1,260
263	Viracta Therapeutics, Inc.@*	VIRX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	0.60	(1.30)	(1.21)	(0.93)	NA	NA	NA	38.6	23
264	Viridian Therapeutics, Inc.	VRDN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	18.05	(4.05)	(5.07)	(3.83)	NA	NA	NA	58.5	1,057
265	Waters Corporation**	WAT	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	326.57	12.02	11.76	11.95	27.2	27.8	27.3	59.1	19,309
266	Wave Life Sciences Ltd.@*	WVE	Outperform	Joseph P. Schwartz	Biopharma / Genetic Medicine	Dec	4.12	(2.05)	(0.36)	(0.64)	NA	NA	NA	119.0	490
267	Werewolf Therapeutics, Inc.	HOWL	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	7.01	(2.02)	(0.65)	0.13	NA	NA	53.9	36.2	254
268	Xencor, Inc.	XNCR	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	19.05	(0.93)	(3.14)	(4.89)	NA	NA	NA	60.9	1,160
269	Xenon Pharmaceuticals Inc.#~	XENE	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	49.10	(2.06)	(2.87)	(3.10)	NA	NA	NA	73.9	3,628
270	Xeris Biopharma Holdings, Inc.	XERS	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease. Endocrine & Biopharma / Emerging	Dec	2.74	(0.70)	(0.43)	(0.25)	NA	NA	NA	138.1	379
271	Zai Lab Ltd	ZLAB	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	19.35	(4.63)	(3.45)	(2.94)	NA	NA	NA	98.8	1,912
272	Zentalis Pharmaceuticals, Inc@*	ZNTL	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	11.63	(4.48)	(4.63)	(3.49)	NA	NA	NA	70.8	823
273	Zymeworks Inc.	ZYME	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	11.67	1.90	(2.29)	(1.06)	6.1	NA	NA	70.0	817

Leerink Partners Coverage List

Updated on: 2/9/2024

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E	Shares Outstanding (MM)	Market Cap (\$MM)
---------	--------	--------	---------	--------	------	--------------------	------------	------------	------------	-------	-------	-------	-----	-------------------------	-------------------

Notes: GAAP presented unless noted; ^ EPS excludes 1x items & other charges; + EPS excludes stock option expense & other stock charges; -operating EPS excludes 1x items & other charges; * operating EPS excludes stock option expense & other charges; ^pro forma EPS excludes 1x items and other charges; ** EPS excludes 1 time charges & amortization of intangibles; ## EPS excludes amortization of intangibles; # EPS IFRS; +++EPS net of royalties; ---EPS excludes stock comp, transaction expenses, & purchase accounting adjustments; @@ EPS excludes changes in fair value of derivative instruments; < Pro forma non-GAAP diluted EPS; #+ EPS diluted, excludes option expense; ``EPS diluted non-GAAP, excludes option expense; ````EPS diluted non-GAAP including excluded items; ^*EPS fully diluted, as converted; #^ EPS excludes 1x items & other charges, but includes option expense; *# Adjusted non-GAAP EPS; **^ EPS diluted, adjusted FAS123R option expense included; +*diluted, adjusted EPS from continuing operations; -+GAAP EPS per ADS; -# USDEPS Fully diluted; #-- EPS-Basic; ~^~ non-GAAP EPS- Basic; @* Diluted EPS; ### Pro forma EPS; -#^ Adjusted/non-GAAP EPS, ex. 1x items; *** Adj. EPS excludes amortization, stock-based comp, & other items not reflective of core operations; ** Adjusted EPS includes impact of RAC release and discreet tax benefits; ^^ 2Q19 EPS adjusted for impact of IPO; ^# Core EPS per ADR; ~-#EPS estimates reflect core EPS, Excl. extraordinary items & reflects IFRS restatement, Incl. options expense.; *#^ Adj. EBITDA; ^^*Non-IFRS diluted EPS; ^*~ Cash EPS

Notes: P/E calculated using prior day closing price and EPS in local currency; Source: FactSet, Company Information, Leerink Partners LLC Research estimates

Disclosure Appendix

Analyst Certification

Each analyst certifies that the views expressed in this report accurately reflect their views and that no part of their compensation was, is, or will be directly related to the specific recommendation or views contained in this report.

Rating Distribution as of 12/31/2023

Coverage Universe	Count	Percent
Outperform (Buy)	185	73.7%
Market Perform (Hold/Neutral)	63	25.1%
Underperform (Sell)	3	1.2%

Rec'd Inv. Banking Serv. in Prev. 12 months	Count	Percent
Outperform (Buy)	71	38.4%
Market Perform (Hold/Neutral)	7	11.1%
Underperform (Sell)	0	0.0%

Explanation of Ratings

Outperform (Buy): We expect this stock to outperform its benchmark over the next 12 months.

Market Perform (Hold/Neutral): We expect this stock to perform in line with its benchmark over the next 12 months.

Underperform (Sell): We expect this stock to underperform its benchmark over the next 12 months.

The degree of outperformance or underperformance required to warrant an Outperform or an Underperform rating should be commensurate with the risk profile of the company.

For the purposes of these definitions the relevant benchmark for "Leerink Partners" branded healthcare and life sciences equity research will be the S&P 600® Health Care Index for issuers with a market capitalization of less than \$2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over \$2 billion.

Important Disclosures

This information (including, but not limited to, prices, quotes and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice. The information is intended for Institutional Use Only and is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this report. The Firm's research analysts, salespeople, traders and other professionals may provide oral or written market commentary or trading strategies that are contrary to opinions expressed in this report. The Firm's asset management group and proprietary accounts may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. Transaction strategies described herein may not be suitable for all investors. This document may not be reproduced or circulated without Leerink Partners' written authority. Additional information is available upon request by contacting the Editorial Department, Leerink Partners, 53 State Street, 40th Floor, Boston, MA 02109.

Like all Firm employees, research analysts receive compensation that is impacted by, among other factors, overall firm profitability, which includes revenues from, among other business units, Institutional Equities, Research, and Investment Banking. Research analysts, however, are not compensated for a specific investment banking services transaction. To the extent Leerink Partners research reports are referenced in this material, they are either attached hereto or information about these companies, including prices, rating, market making status, price charts, compensation disclosures, Analyst Certifications, etc. is available on <https://leerink.bluematrix.com/sellside/Disclosures.action>.

MEDACorp LLC, an affiliate of Leerink Partners, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.

This document may not be reproduced or circulated without our written authority. This document, and any other Leerink Partners research report may not be, in whole or in part, or in any form or manner (i) forwarded, distributed, shared, or made available to third parties, including as input to, or in connection with, any artificial intelligence or machine learning model; (ii) modified or otherwise used to create derivative works; or (iii) used to train or otherwise develop a generative artificial intelligence or machine learning model, without the express written consent of Leerink Partners. Receipt and review of this document constitutes your agreement with the aforementioned limitations in use.

© 2024 Leerink Partners LLC. All Rights Reserved. Member FINRA/SIPC.

Research Management

Jim Kelly

Director of Equity Research
(212) 277-6096
jim.kelly@leerink.com

Julia Belladonna

Associate Director of Research
(212) 404-4524
julia.belladonna@leerink.com

Diversified Biopharmaceuticals

David Risinger, CFA

(212) 404-4539
david.risinger@leerink.com

Bryan R. Dollinger, Ph.D.

(212) 404-4537
bryan.dollinger@leerink.com

Jason Zhuang

(212) 404-4552
jason.zhuang@leerink.com

Targeted Oncology

Andrew Berens, M.D.

(212) 277-6108
andrew.berens@leerink.com

Christopher Liu, Pharm.D.

(212) 277-6192
christopher.liu@leerink.com

Kenneth Shields

(212) 277-6190
ken.shields@leerink.com

Amanda Acosta-Ruiz, Ph.D.

(212) 404-4591
amanda.acostaruz@leerink.com

Emily Shutman

(212) 404-4599
emily.shutman@leerink.com

Immuno-Oncology

Daina M. Graybosch, Ph.D.

(212) 277-6128
daina.graybosch@leerink.com

Jeffrey La Rosa

(212) 277-6103
jeffrey.larosa@leerink.com

Rabib S. Chaudhury, Ph.D.

(212) 277-6268
rabib.chaudhury@leerink.com

Emerging Oncology

Jonathan Chang, Ph.D., CFA

(617) 918-4015
jonathan.chang@leerink.com

Faisal A. Khurshid

(617) 918-4025
faisal.khurshid@leerink.com

Matthew Cowper, M.D.

(617) 918-4890
matthew.cowper@leerink.com

Dylan J. Drakes, Ph.D.

(617) 918-4712
dylan.drakes@leerink.com

Genetic Medicine

Mani Foroohar, M.D.

(212) 277-6089
mani.foroohar@leerink.com

Lili Nsongo, Ph.D.

(212) 277-6229
lili.nsongo@leerink.com

CJ Yeh, M.D.

(212) 404-4552
christopher.yeh@leerink.com

Immunology & Metabolism

Thomas J. Smith

(212) 277-6069
thomas.smith@leerink.com

Nat Charoensook, Ph.D., CFA

(212) 277-6264
nat.charoensook@leerink.com

Brian M. Conley, Ph.D.

(212) 277-6196
brian.conley@leerink.com

Will Humphrey

(212) 277-6255
william.humphrey@leerink.com

Neuroscience

Marc Goodman

(212) 277-6137
marc.goodman@leerink.com

Rudy Li, Ph.D., CFA

(212) 277-6127
rudy.li@leerink.com

Basma Radwan, Ph.D.

(212) 277-6151
basma.radwan@leerink.com

Madhu Yennawar, Ph.D.

(212) 277-6220
madhu.yennawar@leerink.com

Rare Disease

Joseph P. Schwartz

(617) 918-4575
joseph.schwartz@leerink.com

Jenny L. Gonzalez-Armenta, Ph.D.

(212) 277-6221
jenny.gonzalezarmenta@leerink.com

Joori Park, Ph.D.

(617) 918-4098
joori.park@leerink.com

Will Soghikian

(617) 918-4552
will.soghikian@leerink.com

Infectious Disease, Endocrine & Cardiovascular Disorders

Roanna Ruiz, Ph.D.

(212) 277-6144
roanna.ruiz@leerink.com

Rosa Chen, Ph.D.

(212) 404-4522
rosa.chen@leerink.com

Nik Gasic, Pharm.D.

(212) 277-6147
nik.gasic@leerink.com

Life Science Tools & Diagnostics

Puneet Souda

(212) 277-6091
puneet.souda@leerink.com

Isabella Prugue

(212) 277-6126
isabella.prugue@leerink.com

Philip S. Song

(212) 404-4587
philip.song@leerink.com

Michael Sonntag

(212) 277-6048
michael.sonntag@leerink.com

Medical Devices and Technology

Mike Kratky, CFA

(212) 277-6111
mike.kratky@leerink.com

Brett Gasaway

(212) 404-4588
brett.gasaway@leerink.com

Healthcare Providers and Managed Care

Whit Mayo

(629) 802-2560
whit.mayo@leerink.com

John French

(212) 277-6225
john.french@leerink.com

Alberta Massey

(212) 277-6263
alberta.massey@leerink.com

Morgan T. McCarthy

(212) 277-6224
morgan.mccarthy@leerink.com

Editorial

SR. EDITOR/SUPERVISORY ANALYST

Thomas A. Marsilio
(212) 277-6040
thomas.marsilio@leerink.com

SUPERVISORY ANALYSTS

Robert Egan
bob.egan@leerink.com

Mike He
mike.he@leerink.com

Emily Singletary
(212) 277-6115
emily.singletary@leerink.com

Jose Jordan
(212) 404-7236
jose.jordan@leerink.com